Table 1.
Numbers, median ages, age-standardized (European 2013) rates, sex-rate ratios and 5-year relative survival (UK population); HMRN 2004–15
| Total diagnoses | Median age at diagnosis (years) | Annual age-standardized (European 2013) rate per 100 000 (95% CI) | Sex-rate ratio (male/female) | 5-year relative survival | |
|---|---|---|---|---|---|
| All diagnoses (International Classification of Disease for Oncology 3rd edition) | 26 423 | 70.9 | 71.0 (70.7–71.3) | 1.5 (1.5–1.5) | 71.6 (70.9–72.4) |
| Total myeloid | 6576 | 72.5 | 17.7 (17.6–17.9) | 1.5 (1.5–1.6) | 56.3 (54.7–57.9) |
| Acute myeloid leukaemia (9727, 9861, 9871, 9866, 9895, 9896, 9920) | 1629 | 71.8 | 4.4 (4.3–4.4) | 1.5 (1.5–1.6) | 16.8 (14.7–19.1) |
| Acute promyelocytic leukaemia (9866) | 112 | 50.0 | 0.3 (0.3–0.3) | 1.1 (0.9–1.3) | 64.3 (53.5–73.3) |
| Chronic myeloid leukaemia (9875) | 408 | 59.4 | 1.1 (1.0–1.1) | 1.5 (1.4–1.6) | 89.8 (84.8–93.2) |
| Myelodysplastic syndromes (MDS) (9982–9986) | 1494 | 75.8 | 4.1 (4.0–4.2) | 2.5 (2.4–2.6) | 30.2 (27.2–33.3) |
| Myelofibrosis (9961) | 208 | 74.0 | 0.6 (0.6–0.6) | 1.8 (1.6–2.0) | 50.3 (40.4–59.4) |
| Myeloproliferative neoplasms (MPN) (9741, 9950, 9962, 9964, 9975) | 2320 | 71.2 | 6.3 (6.2–6.3) | 1.1 (1.0–1.1) | 93.8 (91.4–95.5) |
| MDS/MPN (9945, 9946, 9975, 9876) | 403 | 76.6 | 1.1 (1.1–1.2) | 2.5 (2.3–2.7) | 21.1 (15.9–26.8) |
| Total lymphoid | 19 836 | 70.4 | 53.2 (53–53.5) | 1.5 (1.5–1.5) | 76.4 (75.6–77.3) |
| B-lymphoblastic leukaemia (9811–9816) | 376 | 12.4 | 0.8 (0.8–0.9) | 1.2 (1.1–1.3) | 67.2 (61.7–72.1) |
| T-lymphoblastic leukaemia (9837) | 104 | 17.6 | 0.2 (0.2–0.3) | 2.1 (1.6–2.7) | 64.7 (53.7–73.7) |
| Chronic lymphocytic leukaemia (9823) | 2800 | 71.6 | 7.6 (7.5–7.7) | 2.0 (2.0–2.1) | 86.0 (83.7–88.0) |
| Hairy cell leukaemia (9940) | 142 | 67.9 | 0.4 (0.4–0.4) | 3.9 (3.3–4.5) | 97.7 (53.9–99.9) |
| Myeloma (9732) | 2749 | 73.0 | 7.5 (7.4–7.6) | 1.7 (1.6–1.7) | 48.5 (46.0–50.9) |
| Plasmacytoma (9731, 9734) | 180 | 68.4 | 0.5 (0.5–0.5) | 2.5 (2.2–2.9) | 62.6 (52.7–71.0) |
| Extranodal marginal zone lymphoma (9699) | 312 | 70.1 | 0.8 (0.8–0.9) | 1.0 (0.9–1.1) | 89.4 (82.8–93.6) |
| Systemic marginal zone lymphoma (9689) | 1198 | 72.9 | 3.3 (3.2–3.3) | 1.6 (1.6–1.7) | 76.0 (72.1–79.4) |
| Follicular lymphoma (9690) | 1310 | 65.0 | 3.5 (3.4–3.5) | 1.0 (1.0–1.0) | 87.5 (84.6–89.9) |
| Mantle cell lymphoma (9673) | 340 | 74.0 | 0.9 (0.9–1.0) | 2.5 (2.3–2.7) | 43.8 (36.8–50.5) |
| Diffuse large B-cell lymphoma (9680) | 3350 | 69.9 | 9.0 (8.9–9.1) | 1.3 (1.3–1.3) | 57.5 (55.5–59.4) |
| Burkitt lymphoma (9687) | 143 | 53.0 | 0.4 (0.3–0.4) | 3.8 (3.1–4.6) | 51.0 (42.1–59.3) |
| Lymphoproliferative disorder NOS | 823 | 77.0 | 2.2 (2.2–2.3) | 1.6 (1.5–1.6) | 81.8 (76.9–85.8) |
| Lymphocyte-predominant nodular Hodgkin lymphoma (9659) | 132 | 45.0 | 0.3 (0.3–0.4) | 3.2 (2.6–3.9) | 99.2 (76.1–100) |
| Classical Hodgkin lymphoma (9650) | 1023 | 41.5 | 2.5 (2.5–2.6) | 1.3 (1.3–1.4) | 85.2 (82.3–87.7) |
| T-cell lymphoma (9837) | 430 | 65.7 | 1.1 (1.1–1.2) | 1.5 (1.4–1.6) | 47.1 (41.6–52.4) |
| T-cell leukaemias (9831–9834) | 178 | 73.6 | 0.5 (0.5–0.5) | 1.0 (0.9–1.1) | 85.4 (74.6–91.9) |
| Monoclonal B-cell lymphocytosis | 1041 | 71.9 | 2.8 (2.8–2.9) | 1.5 (1.5–1.6) | 99.4 (80.0–100) |
| Monoclonal gammopathy of undetermined significance (9765/1) | 3168 | 72.9 | 8.7 (8.6–8.8) | 1.4 (1.4–1.5) | 90.5 (88.5–92.2) |
NOS, not otherwise specified.